Health Sciences Acquisitions Corporation 2
HSAQ
NASDAQ Capital Market13.31
USD
+2.59
- -
CIK
0001814114
ISIN
KYG4411D1097
CUSIP
G4411D109
Return %
Stock
S&P500
1Y
34.72
18.21
3Y
16.75
63.29
5Y
16.75
74.90
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Roderick Tze Ian Wong
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 40 10th Avenue New York City NY United States of America 10014
- IPO Date
- Aug 4, 2020
- CIK
- 0001814114
- Similar Companies
- Business
- Health Sciences Acquisitions Corporation 2 (HSAQ) Health Sciences Acquisitions Corporation 2, a special purpose acquisition company formed in 2020 and headquartered in the Cayman Islands, focuses on mergers, share exchanges, asset acquisitions, or stock purchases targeting innovative companies in biotechnology, pharmaceuticals, medical devices, diagnostics, and healthcare services; it completed its initial public offering in August 2020 raising approximately $139 million. In January 2023, HSAQ completed a reverse merger with Orchestra BioMed Holdings Inc. Orchestra BioMed Holdings, Inc., a New Jersey-based biomedical innovation company specializing in next-generation therapies for cardiovascular disease and other procedure-based medical needs, with the combined entity trading on Nasdaq under the ticker OBIO and receiving $70 million in gross proceeds including investments from Medtronic plc Medtronic plc and RTW Investments. Orchestra BioMed's core products include Atrioventricular Interval Modulation (AVIM) Therapy, also known as BackBeat Cardiac Neuromodulation Therapy (CNT), a bioelectronic device-based treatment for uncontrolled hypertension in pacemaker-indicated patients; Virtue Sirolimus AngioInfusion Balloon (SAB), a drug/device combination delivering extended-release sirolimus during angioplasty for atherosclerotic artery disease without permanent implants; and it operates through risk-reward sharing partnerships with leading medical device firms for global commercialization, targeting large unmet needs in cardiovascular procedures across North America, Europe, and Asia. Recent developments include expanded strategic collaboration with Medtronic in 2025 for AVIM-enabled leadless pacemakers and $71.6 million in committed capital from Medtronic and Ligand Pharmaceuticals Incorporated Ligand Pharmaceuticals Incorporated; a new right of first refusal agreement with Terumo Corporation following termination of their prior distribution deal; securing $147.6 million in total proceeds from strategic transactions, public and private offerings; initiation of patient enrollment in the Virtue Trial versus paclitaxel-coated balloons; and FDA-approved protocol enhancements for the BACKBEAT pivotal study, expanding eligible patients more than 24-fold, positioning the company for key clinical milestones in 2026-2027.
Defiance Daily Target 2X Long LMND ETF (NASDAQ:LMNX) & Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) Critical Comparison
Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) Trading Up 1.3% – Here’s What Happened
Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) Shares Down 2.9% – Should You Sell?
Comparing Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) & INVO Fertility (NASDAQ:IVF)